An observational study in Non-Small Cell Lung Cancer, sponsored by Three Gorges Hospital of Chongqing University. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Three Gorges Hospital of Chongqing University · Observational
Among 1,877 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 985 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.
Among the 1,877 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 282nd largest by enrollment of the 286 observational ones that give a count, is one of 203 that started in 2024, is one of 286 observational ones, and was the 1,365th registered.
7,620 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →762 of the 1,877 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Daiichi Sankyo · Sites in China, United States, Argentina and 10 more countries
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 986 (74%) set no upper age limit and 226 (17%) stop at 75 or younger; 34 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,877 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 360 · Phase 2 846 · Phase 3 404 · Phase 4 40
First in 1996; this study’s year is marked. 203 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 160 across 1,148 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 100 across the 1,591 interventional studies, 200 across the 286 observational. Of the 453 that completed or were terminated, 130 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
803 of 1,877 have an industry lead sponsor. The 10 most frequent:
Three Gorges Hospital of Chongqing University is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Three Gorges Hospital of Chongqing University has 2 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
226 of the studies in Carcinoma, Non-Small-Cell Lung with a site in China that are under way reach primary completion within a year, 33 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448312Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06704620Phase 3Tianjin Medical University Cancer Institute and HospitalStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT05429463Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNeoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） | 2026-11-30 |
| NCT06711900Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2026-12 |
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
Add all 226 to your calendar (.ics) → With an account.
Among the 1,877 studies in Carcinoma, Non-Small-Cell Lung with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rationale:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the world, and patients with stage IIIB-IV have a poor prognosis. EGFR mutations, especially the 19th amino acid deletion (19del) and the 21st amino acid L858R mutation, are the most common types of gene mutations in NSCLC. These mutations usually lead to overactivity of EGFR, thereby stimulating excessive proliferation of lung cancer cells. At present, the conventional treatment for such patients is mainly the use of EGFR tyrosine kinase inhibitors (EGFR-TKIs) for treatment. However, although EGFR-TKIs have achieved certain results in the treatment of NSCLC patients with EGFR mutations, their treatment effects are often difficult to sustain due to the resistance of patients to these drugs. Therefore, finding new treatment strategies to improve the survival rate and quality of life of such patients is an important current research direction. The results of many studies suggest that EGFR TKIs and anti-angiogenic drugs can inhibit tumors from different signaling pathways. EGFR-TKIs can inhibit the epidermal growth factor receptor pathway and inhibit tumor growth; anti-angiogenic drugs inhibit tumor angiogenesis by binding to vascular endothelial growth factor (VEGF). At the same time, the combination of the two has a synergistic effect. Both EGFR and VEGFR-2 signaling pathways can trigger downstream signaling pathways such as PI3K/AKT and RAS/RAF/ERK, affecting cell proliferation. EGFR activation can also drive HIF-1α upregulation, leading to VEGF gene expression. Many clinical studies have confirmed that the A+T treatment model can improve the efficacy of EGFR-positive NSCLC.
Methods:
This study is planned to adopt a mixed design. We will prospectively collect new patient data and retrospectively analyze existing patient data. In the prospective part, we will treat patients with stage IIIB-IV NSCLC with EGFR amino acid 21 L858R mutation and amino acid 19 deletion (19del) with a combination of ametinib mesylate (AUMOLERTINIB) and recombinant human endostatin (ENDOSTAR). In the retrospective part, we will extract the existing data of patients treated with AUMOLERTINIB alone from the hospital\'s electronic medical record system as a control group. The primary endpoint is progression free survival (PFS). Secondary endpoints are objective response rate (ORR), duration of response (DoR), adverse events (AE), quality of life (EORTCQLQ-L13) score, anxiety and depression self-rating scale (HADS) and patient health questionnaire-9 (PHQ-9).
Route:
In the prospective part, we will perform genetic testing on patients to determine their EGFR mutation status. Then, we will treat patients with stage IIIB-IV NSCLC with EGFR amino acid 21 L858R mutation and amino acid 19 deletion with ametinib mesylate and recombinant human endostatin, and match the corresponding data in the hospital database. We will regularly follow up patients participating in the prospective study, collect data on their disease progression and survival, and perform statistical analysis on these data to evaluate the effectiveness and safety of the combination therapy.
Expected:
We expect that the combination of ametinib mesylate and recombinant human endostatin can improve the survival rate and quality of life of patients with stage IIIB-IV NSCLC with EGFR amino acid 21 L858R mutation and amino acid 19 deletion. This is mainly because ametinib mesylate and recombinant human endostatin target EGFR hyperactivity and angiogenesis, two processes that play a key role in the development of NSCLC, respectively, so their combined use may produce a synergistic effect, thereby improving the therapeutic effect.
Patients with stage IIIB-IV NSCLC carrying EGFRL858R mutation and 19th amino acid deletion (19del).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the prospective part, we will treat newly enrolled patients with the combination of Almonertinib and Endostar.
we will extract the data of patients who previously used Almonertinib alone from the hospital database as the control group.
progression-free survival (PFS)
Refers to the time from the start of a randomized clinical trial to tumor progression (in any aspect) or death from any cause.
Time frame: 3 months
objective response rate
Refers to the proportion of patients whose tumors shrink or stabilize for a certain period of time, including cases of complete remission (CR), partial remission (PR) and stable disease (SD)
Time frame: 3 months
Adverse events
Adverse medical events that occur after a clinical trial participant receives a drug
Time frame: 3 months
Global Health Status/Quality of Life Measured by EORTC QLQ-C30
Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The global health status/quality of life (GHS/QoL) scale score ranges from 0 to 100; higher scores indicate better quality of life.
Time frame: 3 months
Depressive Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9)
Assessed using the Patient Health Questionnaire-9 (PHQ-9). The total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms.
Time frame: 3 months
Anxiety Symptoms Measured by HADS Anxiety Subscale (HADS-A)
Assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The subscale score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms.
Time frame: 3 months
Depressive Symptoms Measured by HADS Depression Subscale (HADS-D)
Assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The subscale score ranges from 0 to 21; higher scores indicate more severe depressive symptoms.
Time frame: 3 months
Duration of Remission
refers to the time from the first assessment of CR or PR to the first assessment of PD or death from any cause.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Jul 2026, 30 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Three Gorges Hospital of Chongqing University